Non-Motor Symptoms in Patients with Parkinson’s Disease – Correlations with Inflammatory Cytokines in Serum
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Parkinson's Disease (PD) is the second most common neurodegenerative disorder of the central nervous system. Motor symptoms are the focus of pharmacotherapy, yet non-motor features of the disease (e.g. fatigue, mood disturbances, sleep disturbances and symptoms of anxiety) are both common and disabling for the patient. The pathophysiological mechanisms behind the non-motor symptoms in PD are yet to be untangled. The main objective of this study was to investigate associations between pro-inflammatory substances and non-motor symptoms in patients with PD. METHODS AND MATERIALS: We measured C-reactive protein, interleukin (IL)-6, soluble IL-2 receptor (sIL-2R) and tumor necrosis factor-α (TNF-α) in blood samples from PD patients (n=86) and healthy controls (n=40). Symptoms of fatigue, depression, anxiety and sleeping difficulties were assessed using the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT), the Hospital Anxiety and Depression Scale (HAD), and the Scales for Outcome in PD-Sleep Scale respectively. RESULTS: IL-6 was significantly higher in PD patients than in healthy controls. Compared to healthy controls, PD patients displayed significantly higher mean scores on HAD and lower scores on FACIT, thus indicating more severe symptoms as measured with these scales. Within the PD sample, high levels of both sIL-2R and TNF-α were significantly associated with more severe symptoms assessed by means of FACIT and HAD (depression and anxiety subscales). SIL-2-R levels were able to significantly predict FACIT and HAD scores after the effects of age, gender, anti-parkinsonian medications, and severity of motor symptoms were controlled for. DISCUSSION: We suggest that non-motor symptoms in PD patients, such as fatigue and depressive symptoms, might be generated via inflammatory mechanisms. This knowledge might contribute to the development of novel treatment options in PD, specifically targeting non-motor symptoms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Increased levels of IL-6 in PD patients’ serum have been reported in a number of studies [254,255,256]”
From Ageing, Cellular Senescence and Neurodegenerative Disease (2018) · cites this paper as [254]
In the citing paper
“proinflammatory cytokines could play a role in the nonmotor symptoms of PD [42]”
From Neuroprotective Effect of Ceftriaxone on MPTP‐Induced Parkinson’s Disease Mouse Model by Regulating Inflammation and Intestinal Microbiota (2021) · cites this paper as [42]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Hospital Anxiety and Depression Scale
Zigmond, A. S., & Snaith, R. P. (1983) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1983.tb09716.x · Cited by 47,139
Systematic review of levodopa dose equivalency reporting in Parkinson's disease
Tomlinson, C. L., Stowe, R., Patel, S., Rick, C., Gray, R., & Clarke, C. E. (2010) · Movement Disorders · doi:10.1002/mds.23429 · Cited by 4,219
Epidemiology of Parkinson's disease
de Lau, L. M., & Breteler, M. M. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70471-9 · Cited by 4,110
Diagnostic Criteria for Parkinson Disease
Gelb, D. J., Oliver, E., & Gilman, S. (1999) · Archives of Neurology · doi:10.1001/archneur.56.1.33 · Cited by 2,822
Interleukin-2: Inception, Impact, and Implications
Smith, K. A. (1988) · Science · doi:10.1126/science.3131876 · Cited by 2,153
Twenty years of research on cytokine-induced sickness behavior
Dantzer, R., & Kelley, K. W. (2007) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2006.09.006 · Cited by 1,420
Cytokines and major depression
Schiepers, O. J. G., Wichers, M. C., & Maes, M. (2005) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2004.11.003 · Cited by 1,235 · cited 5×
“However, there are preliminary clinical trials of MDD patients without PD indicating that NSAIDs as add-on to conventional antidepressants may have beneficial effects on depressive symptoms [42,43].”
InfluentialLiu, Y., Ho, R. C.-M., & Mak, A. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.08.003 · Cited by 948
Hospital Anxiety and Depression Scale
Zigmond, A. S., & Snaith, R. P. (2013) · PsycTESTS Dataset · doi:10.1037/t03589-000 · Cited by 946
Blum-Degena, D., Müller, T., Kuhn, W., Gerlach, M., Przuntek, H., & Riederer, P. (1995) · Neuroscience Letters · doi:10.1016/0304-3940(95)12192-7 · Cited by 801
Cited by
Items 201–250 of 250
COPPADIS Study Group, Santos‐García, D., Mir, P., Cubo, E., Vela, L., Rodríguez-Oroz, M. C., Martí, M. J., Arbelo, J. M., Infante, J., Kulisevsky, J., et al. (2016) · BMC Neurology · doi:10.1186/s12883-016-0567-6 · Cited by 2
Nomoto, M., Tsuboi, Y., Kashihara, K., Chiu, S., Maeda, T., Saiki, H., Watanabe, H., Shimo, Y., Hattori, N., Yamaguchi, T., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0309297 · Cited by 1
Alzheimer’s Disease: Link to Aging and Epigenetics
Zala, D. K., Banerjee, S., & Tiwari, A. K. (2025) · RNA technologies · doi:10.1007/978-3-031-91072-2_15 · Cited by 1
Taneva, S. G., Todinova, S. J., Danailova, A., Atanassov, K. T., & Atanassova, V. (2026) · Journal of Thermal Analysis and Calorimetry · doi:10.1007/s10973-025-15269-3 · Cited by 1
Shen, Q., Lv, A., Li, Y., Liu, P., Yang, J., Wang, S., & Guo, H. (2026) · Neurogastroenterology & Motility · doi:10.1111/nmo.70289 · Cited by 1
de Almeida, C. M. O., Filho, M. F. D. V., Said, R. C., Dantas, J. M., Azedo, A. L., Ferreira, M. C., Noronha, E. A., Perez, Y. G., Sobreira-Neto, M. A., Lopes, A. L. R. B., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1808550 · Cited by 1
Weber, H., Statz, M., Casadei, N., Rieß, O., Richter, F., Hermann, W., Storch, A., & Fauser, M. (2026) · npj Parkinson s Disease · doi:10.1038/s41531-026-01436-2 · Cited by 1
Changes in the Immune System in Parkinson’s Disease
Romero‐Ramos, M. (2017) · Springer eBooks · doi:10.1007/978-3-319-64597-1_150-1 · Cited by 1
Özer, G., Adıgüzel, H., Kırmacı, Z. İ. K., & Ergün, N. (2019) · Journal of Surgery and Medicine · doi:10.28982/josam.521927 · Cited by 1
Lin, H., Chang, S., Wu, P.-H., & Kao, C.-Y. (2022) · Journal of Men s Health · doi:10.31083/j.jomh1809185 · Cited by 1
Neuroinflammation, glymphatic system, and Parkinson's disease
Saleh, S. M. S., Nasser, N., Tharwat, E. K., Elbehiry, T., & Helmy, H. I. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-16128-5.00001-3 · Cited by 1
Pinheiro, R. M. C. (2014) · Americanae (AECID Library)
Infl ammatory Biomarkers of Brain Injury and Disease
Johnson, E. A., Yassin, W., & Guignet, M. A. (2014) · CRC Press eBooks · doi:10.1201/b17644-17
Schutt, C. R. (2017) · DigitalCommons@UNMC
Saraiva, C. (2017) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Biomarcadores diagnósticos y de deterioro cognitivo en la enfermedad de Parkinson
Delgado‐Alvarado, M. (2017) · Communities in ADDI (University of the Basque Country)
Role of Interferon-Gamma and Leucine-Rich Repeat Kinase 2 in Stress-Related Pathology
Litteljohn, D. (2016) · Carleton University's Institutional Repository (MacOdrum Library, Carleton University) · doi:10.22215/etd/2016-11660
Ghrelin-axis function in the context of Adult Hippocampal Neurogenesis
Hornsby, A. K. E. (2018) · Cronfa (Swansea University) · doi:10.23889/suthesis.50587
Insulin resistance and Parkinson’s disease
Farooqui, A. A. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819603-8.00007-9
Clinical Trials for Depression, Anxiety, Fatigue, and Apathy in Parkinson’s Disease
Škorvánek, M., & Baláž, M. (2020) · Neuromethods · doi:10.1007/978-1-0716-0912-5_10
Interrelationship between Gut microbiota and Parkinson’s disease
Shivananjappa, M. M., Manasa, R., Prakruthi, M., & Shekhara Naik, R. (2020) · IP Journal of Nutrition Metabolism and Health Science · doi:10.18231/j.ijnmhs.2020.015
Inflammatory Biomarkers of Brain Injury and Disease
Johnson, E. A., Yassin, W., & Guignet, M. A. (2014) · CRC Press eBooks · doi:10.1201/b17644-13
Changes in the Immune System in Parkinson’s Disease
Romero‐Ramos, M. (2019) · Springer eBooks · doi:10.1007/978-3-319-99375-1_150
Sortwell, C. E., & Duffy, M. F. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.728777047.793554721
Duarte, E. B. C., dos Santos, E. U. D., Cândido, S. A., de Lima, G. D. C., Asano, A. G., Asano, N. M. J., Maia, M. D. M. D., & de Souza, P. R. E. (2023) · Seven Editora eBooks · doi:10.56238/cienciasaudeestuepesv1-086
Neuroinflammation Imaging in Neurodegenerative Diseases
Hammoud, D. A., & Herscovitch, P. (2023) · Springer eBooks · doi:10.1007/978-3-031-35098-6_9
Relationship between nonmotor symptoms and neutrophil-to-lymphocyte ratio in Parkinson’s disease
İşçan, D., Demirtaş, G., & Demirtaş, A. (2024) · Çukurova medical journal (Online)/Çukurova medical journal · doi:10.17826/cumj.1503745
Current Physiotherapy Approaches in Individuals with Parkinson’s Disease
Özden, F., Özkeskin, M., & Başer, M. (2025) · Springer eBooks · doi:10.1007/978-3-032-11375-7_390
Neuroimaging in Psychoneuroimmunology Research
Chand, T., Gupta, R., Verma, K., & Nayak, K. (2025) · Advances in medical diagnosis, treatment, and care (AMDTC) book series · doi:10.4018/979-8-3693-7432-0.ch011
Association between Inflammation and Chronic Fatigue Syndrome in Parkinson’s Disease
Никитина, М. А., Bragina, E. Y., Ivanova, S. А., Boyko, A. S., Levchuk, L. A., Nazarenko, M. S., & Alifirova, V. M. (2025) · Neuroscience and Behavioral Physiology · doi:10.1007/s11055-025-01795-y
Ανοσογενετικός κίνδυνος στην νόσο Πάρκινσον
Μαρογιάννη, Χ. (2025) · doi:10.12681/eadd/59241
Noninvasive transcranial brain stimulation to treat fatigue in chronic diseases
Kuehne, M., Linnhoff, S., & Zaehle, T. (2025) · Handbook of behavioral neuroscience · doi:10.1016/b978-0-443-26602-7.00029-4
Prietzel, K. A. (2024) · University of Regensburg Publication Server (University of Regensburg) · doi:10.5283/epub.59232
Estudio de la respuesta inmune periférica en la enfermedad de Parkinson
Muñoz‐Delgado, L. (2023) · Deposito de Investigacion Universidad de Sevilla (University of Seville)
Avaliação de receptores similares a toll (tlrs) em monócitos de pacientes com doença de Parkinson
Sobrinho, H. M. D. R. (2017) · Americanae (AECID Library)
Linse, K. (2016) · Qucosa (Saxon State and University Library Dresden)
INVESTIGATING NEUROINFLAMMATION IN SPORADIC AND LRRK2-ASSOCIATED PARKINSON'S DISEASE
Badanjak, K. (2022) · Open Repository and Bibliography (University of Luxembourg)
Dissecting the impact of cellular senescence on muscle regeneration
Cazin, C. (2020) · theses.fr (ABES) · doi:10.70675/42a7ff38zb338z4eb8za925z2ce0a01ee74e
I, Traktirov, D. S., Kulikova, E., Burdinskaya, V. O., Muruzheva, Z. M., & Karpenko, M. N. (2026) · Biomedicine · doi:10.51248/v46i1.206
Neuroprotective Potential of Ocimum basilicum: Inslight into Mechanisms and Therapeutic Applications
., C., Upadhayay, A., Kumar, P., Kumar, A., Tanwar, B., & Nitu (2026) · International Journal of Innovative Science and Research Technology (IJISRT) · doi:10.38124/ijisrt/26apr2419
Ying, J., Fang, Z., Zhang, C. L., Liu, X., Cui, J., Li, Z., & Tang, J. (2026) · Health care science · doi:10.1002/hcs2.70087
Inflammation and neuropsychiatric symptoms in Parkinson's disease: a genetic association
Gonçalves, A. R., Mendes, A., Damásio, J., Vila‐Chã, N., Boleixa, D., Santos, C., Leal, B., & Cavaco, S. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2026.1877657
Islam, M. S., Islam, M. T., Mondol, M., Islam, I., Fuad, K. M., Abid, M. F., Tajim, S., & Ferdous, R. (2026) · Advances in Redox Research · doi:10.1016/j.arres.2026.100196
Major Depressive Disorder as a Comorbidity in Neurological Diseases
Izadpanah, M., Vahidinia, Z., Dahmardeh, N., & Bahlakeh, G. (2026) · IGI Global eBooks · doi:10.4018/979-8-2600-4270-0.ch005
da Silva, N. M., & Maia, A. M. L. R. (2023) · EXTENDERE
Jiménez‐Román, S., Mena, J., Adamuz, D., Tuset, A., Mallo, M., Albarracín, A. M., Samaniego, D., Ispierto, L., Vilas, D., Álvarez, R., et al. (2026) · Movement Disorders · doi:10.1002/mds.70529
Chu, Y., Wang, B.-Y., Qu, C.-Y., Lan, Y., Wang, L., & Mao, M. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2026.1967946
Soto-Diaz, K., Vailati-Riboni, M., Louie, A. Y., McKim, D. B., Gaskins, H. R., Johnson, R. W., & Steelman, A. J. (2021) · doi:10.3389/fimmu.2021.734349.s007
Metadata
- Authors
- Lindqvist, D., Kaufman, E., Brundin, L., Hall, S., Surova, Y., & Hansson, O.
- Affiliations
- Lund University (SE)
- Corresponding author
- Lindqvist, Daniel
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2012-10-17
- Volume
- 7
- Issue
- 10
- Pages
- e47387
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3474801
- OpenAlex
- W2107646604
- Cited by
- 236
- References
- 48
- Citations by year
- 2026: 14 · 2025: 19 · 2024: 22 · 2023: 19 · 2022: 27 · 2021: 21 · 2020: 17 · 2019: 16 · 2018: 16 · 2017: 13 · 2016: 15 · 2015: 15 · 2014: 16 · 2013: 6
- FWCI
- 7.74
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Lund University Publications (Lund University) (submittedVersion, other-oa)
- Funders
- Lunds Universitet
- Vetenskapsrådet
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
- Keywords
- Parkinson's disease, non-motor symptoms, fatigue, depression, anxiety, sleep disorders, inflammatory cytokines, interleukin-6, soluble interleukin-2 receptor, TNF-α, C-reactive protein, neuroinflammation
- MeSH terms
- C-Reactive Protein, Female, Humans, Male, Middle Aged, Motor Activity, Parkinson Disease, Regression Analysis, Tumor Necrosis Factor-alpha, Receptors, Interleukin-2, Interleukin-6, Confounding Factors, Epidemiologic, Case-Control Studies, Cytokines, Inflammation Mediators
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.